| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.2190315 |
| P698 | PubMed publication ID | 2190315 |
| P2093 | author name string | R F Siliciano | |
| G E Smith | |||
| J E Hildreth | |||
| M Polydefkis | |||
| M L Clements | |||
| R J Orentas | |||
| E Obah | |||
| P2860 | cites work | Introduction of soluble protein into the class I pathway of antigen processing and presentation | Q46305448 |
| P433 | issue | 4960 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 1234-1237 | |
| P577 | publication date | 1990-06-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine | |
| P478 | volume | 248 |
| Q40049315 | A CD4+ cytotoxic T-lymphocyte clone to a conserved epitope on human immunodeficiency virus type 1 p24: cytotoxic activity and secretion of interleukin-2 and interleukin-6 |
| Q35873361 | Analysis of the human env-specific cytotoxic T-lymphocyte (CTL) response in natural human immunodeficiency virus type 1 infection: low prevalence of broadly cross-reactive env-specific CTL. |
| Q35886254 | Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160. |
| Q36684398 | Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. |
| Q27469356 | Bystander target cell lysis and cytokine production by dengue virus-specific human CD4(+) cytotoxic T-lymphocyte clones |
| Q33834466 | CD4(+) T cells and gamma interferon in the long-term control of persistent friend retrovirus infection |
| Q41588172 | CD4+Human Immunodeficiency Virus Type 1 (HIV-1) Envelope-Specific Cytotoxic T Lymphocytes Derived from the Peripheral Blood Cells of an HIV-1-Infected Individual |
| Q67899864 | Cellular and humoral antigenic epitopes in HIV and SIV |
| Q37284795 | Chimeric gag-V3 virus-like particles of human immunodeficiency virus induce virus-neutralizing antibodies |
| Q39122674 | Clonally expanded cytotoxic CD4+ T cells and the pathogenesis of IgG4-related disease |
| Q41916926 | Comparative analysis of the capacity of elite suppressor CD4+ and CD8+ T cells to inhibit HIV-1 replication in monocyte-derived macrophages |
| Q36232089 | Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines |
| Q41663440 | Cross-Neutralizing Antibodies in Rabbits Immunized with HIV-1 gp160 Purified from Simian Cells Infected with a Recombinant Vaccinia Virus |
| Q36648079 | Cross-reactive lysis of human targets infected with prototypic and clinical human immunodeficiency virus type 1 (HIV-1) strains by murine anti-HIV-1 IIIB env-specific cytotoxic T lymphocytes |
| Q45738849 | Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1(SF-2) recombinant GP120. |
| Q57259646 | Cytotoxic HIV-1 p55ᵍᵃᵍ-Specific CD4+ T Cells Produce HIV-Inhibitory Cytokines and Chemokines |
| Q40393228 | Cytotoxic T Lymphocytes in Human Immunodeficiency Virus Infection: Responses to Structural Proteins |
| Q36638218 | Cytotoxic activity against maedi-visna virus-infected macrophages |
| Q34194927 | Cytotoxic and proliferative T cell responses in HIV-1-infected Macaca nemestrina |
| Q46887236 | Different regulatory and cytotoxic CD4+ T lymphocyte profiles in renal transplants with antibody-mediated chronic rejection or long-term good graft function. |
| Q36624976 | Direct injection of a recombinant retroviral vector induces human immunodeficiency virus-specific immune responses in mice and nonhuman primates |
| Q27003380 | Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse model |
| Q36137980 | Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein |
| Q37313358 | Enhancement of human immunodeficiency virus (HIV)-specific CD4+ and CD8+ cytotoxic T-lymphocyte activities in HIV-infected asymptomatic patients given recombinant gp160 vaccine |
| Q41587736 | Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope |
| Q40673123 | Epstein-Barr virus-transformed B cells, a potentially convenient source of autologous antigen-presenting cells for the propagation of certain human cytotoxic T lymphocytes. |
| Q36625106 | Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1. |
| Q40874348 | Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif |
| Q47094945 | HIV Env conserved element DNA vaccine alters immunodominance in macaques |
| Q44358472 | HIV vaccine therapy |
| Q33646313 | High major histocompatibility complex-unrestricted lysis of simian immunodeficiency virus envelope-expressing cells predisposes macaques to rapid AIDS progression |
| Q42767811 | Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins |
| Q33933855 | Human immunodeficiency virus type 1 major neutralizing determinant exposed on hepatitis B surface antigen particles is highly immunogenic in primates |
| Q45856052 | Immunization with subunit human immunodeficiency virus vaccine generates stronger T helper cell immunity than natural infection |
| Q36633526 | Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine |
| Q35869862 | Induction of anti-gp160 cytotoxic T cells cross-reacting with various V3 loop P18 peptides in human immunodeficiency virus type 1 envelope-immunized individuals. |
| Q34787140 | Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein |
| Q33935668 | Induction of feline immunodeficiency virus-specific cytolytic T-cell responses from experimentally infected cats |
| Q34171623 | Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160 |
| Q45860432 | Inverse relationship of CD8+CD11+ suppressor T cells with human immunodeficiency virus (HIV)-specific cellular cytotoxicity and natural killer cell activity in HIV infection |
| Q40155706 | Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis |
| Q37599231 | Macromolecular assemblage in the design of a synthetic AIDS vaccine |
| Q33757364 | Mapping of specific and promiscuous HLA-DR-restricted T-cell epitopes on the Plasmodium falciparum 27-kilodalton sexual stage-specific antigen. |
| Q36601816 | Milestones leading to the genetic engineering of baculoviruses as expression vector systems and viral pesticides |
| Q39604412 | Multiple effector functions mediated by human immunodeficiency virus-specific CD4(+) T-cell clones |
| Q36697604 | Mutation of human immunodeficiency virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes |
| Q37255619 | Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice |
| Q24634681 | Pathogenesis of human immunodeficiency virus infection |
| Q57160272 | Pigs that recover from porcine reproduction and respiratory syndrome virus infection develop cytotoxic CD4+CD8+ and CD4+CD8- T-cells that kill virus infected cells |
| Q41706764 | Production of Immunogenic HIV-1 Viruslike Particles in Stably Engineered Monkey Cell Lines |
| Q34609562 | Prospects for immune reconstitution in HIV-1 infection |
| Q42616181 | Recombinant Virus Vaccine-Induced SIV-specific CD8 + Cytotoxic T Lymphocytes |
| Q45786678 | Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes |
| Q36175538 | Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160. |
| Q58328348 | Role of Cellular Immunity in Protection against HIV Infection**This article was accepted for publication on 31 October 1996 |
| Q41588346 | Role of flanking variable sequences in antigenicity of consensus regions of HIV gp120 for recognition by specific human T helper clones |
| Q41597581 | Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. NIAID AIDS Vaccine Clinical Trials Network |
| Q43096910 | Strong ability of Nef-specific CD4+ cytotoxic T cells to suppress human immunodeficiency virus type 1 (HIV-1) replication in HIV-1-infected CD4+ T cells and macrophages |
| Q33798409 | T-cell receptor-mediated anergy of a human immunodeficiency virus (HIV) gp120-specific CD4(+) cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide |
| Q36060423 | The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope |
| Q34460375 | The basis for HIV immunotherapeutic vaccines |
| Q46361950 | The use of the clinical immunology laboratory |
| Q41542329 | Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T cells |
| Q44046042 | Vaccination for Disease |
| Q45746020 | Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies |
| Q35848078 | Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. |
Search more.